TickerFacts.

Compare

10x Genomics, Inc. vs Cytek Biosciences, Inc. vs Pacific Biosciences of California, Inc. vs Bio-Rad Laboratories, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year10x Genomics, Inc.
TXG		Cytek Biosciences, Inc.
CTKB		Pacific Biosciences of California, Inc.
PACB		Bio-Rad Laboratories, Inc.
BIO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$642.82M$201.49M$160.00M$2.58B
Revenue growth (YoY)+5.2%+0.5%+3.9%+0.7%
Gross margin69.1%51.8%28.6%51.9%
Operating margin-9.5%-20.0%-346.2%1.8%
Net margin-6.8%-33.0%-341.5%29.4%
Net income-$43.54M-$66.54M-$546.38M$759.90M
EPS (Diluted)-$0.35n/a-$1.82$27.85
Operating cash flow$136.05M-$4.69M-$111.21M$532.20M
Free cash flow$130.12M-$8.77M-$113.92M$374.60M
Cash & equivalentsn/a$90.85M$63.71M$529.80M
Total assets$1.04B$461.54M$784.08M$10.58B
Total liabilities$245.04M$119.80M$778.73M$3.12B
Shareholders' equity$796.33M$341.74M$5.35M$7.45B
Return on year-end equity-5.5%-19.5%n/m10.2%
Shares outstanding127.69M128.55M301.96Mn/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year10x Genomics, Inc.Cytek Biosciences, Inc.Pacific Biosciences of California, Inc.Bio-Rad Laboratories, Inc.
Latest$642.82M
Ended 2025-12-31		$201.49M
Ended 2025-12-31		$160.00M
Ended 2025-12-31		$2.58B
Ended 2025-12-31
1 year earlier$610.78M
Ended 2024-12-31		$200.45M
Ended 2024-12-31		$154.01M
Ended 2024-12-31		$2.57B
Ended 2024-12-31
2 years earlier$618.73M
Ended 2023-12-31		$193.01M
Ended 2023-12-31		$200.52M
Ended 2023-12-31		$2.67B
Ended 2023-12-31
3 years earlier$516.41M
Ended 2022-12-31		$164.04M
Ended 2022-12-31		$128.30M
Ended 2022-12-31		$2.80B
Ended 2022-12-31
4 years earlier$490.49M
Ended 2021-12-31		$127.95M
Ended 2021-12-31		$130.51M
Ended 2021-12-31		$2.92B
Ended 2021-12-31